Company news

MBX Biosciences, Inc. news in 2026

MBX Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights

November 9, 2026

MBX Biosciences to Participate in Upcoming November Investor Conferences

October 13, 2026

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer

September 8, 2026

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

August 27, 2026

MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights

August 6, 2026

MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth

July 13, 2026

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

June 12, 2026

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

June 1, 2026

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

May 26, 2026

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

May 10, 2026

MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award

May 7, 2026

MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio

April 23, 2026

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 2, 2026

MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

March 12, 2026

MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

March 9, 2026

MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

March 8, 2026

CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

March 8, 2026

MBX Biosciences to Participate in Upcoming March Investor Conferences

February 22, 2026

MBX Biosciences to Participate in Upcoming Investor Conferences

February 11, 2026

MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair

January 21, 2026

MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference

January 10, 2026

Decks in 2026